Insulet Corporation

DB:GOV Stock Report

Market Cap: €17.3b

Insulet Valuation

Is GOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GOV (€246.6) is trading above our estimate of fair value (€202.78)

Significantly Below Fair Value: GOV is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GOV?

Key metric: As GOV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GOV. This is calculated by dividing GOV's market cap by their current earnings.
What is GOV's PE Ratio?
PE Ratio43.4x
EarningsUS$420.90m
Market CapUS$18.25b

Price to Earnings Ratio vs Peers

How does GOV's PE Ratio compare to its peers?

The above table shows the PE ratio for GOV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.5x
AFX Carl Zeiss Meditec
25.5x16.3%€5.2b
SHL Siemens Healthineers
28.3x14.2%€56.0b
EUZ Eckert & Ziegler
21.1x4.6%€802.1m
DRW3 Drägerwerk KGaA
7.2x2.0%€792.8m
GOV Insulet
43.4x1.8%€18.2b

Price-To-Earnings vs Peers: GOV is expensive based on its Price-To-Earnings Ratio (43.4x) compared to the peer average (20.8x).

Price to Earnings Ratio vs Industry

How does GOV's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GOV 43.4xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GOV is expensive based on its Price-To-Earnings Ratio (43.4x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is GOV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GOV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio43.4x
Fair PE Ratio23.5x

Price-To-Earnings vs Fair Ratio: GOV is expensive based on its Price-To-Earnings Ratio (43.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GOV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€246.60
€257.89
+4.6%
7.9%€297.54€219.63n/a22
Nov ’25€215.20
€227.78
+5.8%
9.3%€261.77€169.92n/a21
Oct ’25€210.80
€218.83
+3.8%
9.2%€257.47€167.13n/a21
Sep ’25€182.70
€211.77
+15.9%
7.4%€236.04€165.41n/a21
Aug ’25€181.90
€215.74
+18.6%
9.0%€249.32€170.83n/a21
Jul ’25€182.30
€215.74
+18.3%
9.0%€249.32€170.83n/a21
Jun ’25€162.90
€215.74
+32.4%
9.0%€249.32€170.83n/a21
May ’25€161.05
€217.62
+35.1%
7.0%€248.70€191.59n/a20
Apr ’25€157.20
€218.89
+39.2%
7.0%€250.29€192.82n/a20
Mar ’25€155.45
€218.20
+40.4%
7.6%€248.83€191.69n/a20
Feb ’25€179.05
€213.43
+19.2%
11.5%€248.10€149.78n/a20
Jan ’25€195.90
€206.06
+5.2%
13.5%€245.40€148.15n/a20
Dec ’24€176.20
€200.17
+13.6%
16.1%€254.88€148.38n/a20
Nov ’24€128.25
€235.95
+84.0%
21.1%€332.92€151.92€215.2020
Oct ’24€150.75
€258.58
+71.5%
17.5%€336.11€175.16€210.8018
Sep ’24€176.10
€266.23
+51.2%
15.0%€328.48€192.46€182.7018
Aug ’24€246.00
€313.80
+27.6%
8.7%€340.76€212.64€181.9018
Jul ’24€263.90
€314.43
+19.1%
8.6%€340.84€212.68€182.3018
Jun ’24€252.60
€314.43
+24.5%
8.6%€340.84€212.68€162.9018
May ’24€287.60
€307.77
+7.0%
8.7%€342.30€213.60€161.0517
Apr ’24€293.00
€305.15
+4.1%
9.3%€345.71€215.72€157.2016
Mar ’24€264.50
€308.33
+16.6%
9.8%€351.71€219.47€155.4516
Feb ’24€262.85
€292.77
+11.4%
11.7%€328.83€202.93€179.0516
Jan ’24€275.70
€292.46
+6.1%
12.0%€330.26€203.82€195.9016
Dec ’23€292.00
€292.31
+0.1%
12.0%€338.63€208.98€176.2016
Nov ’23€267.80
€277.62
+3.7%
12.5%€346.24€190.68€128.2516

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$50.67

7D

-2.6%

1Y

-18.8%

Fagron

€1.4b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.54

7D

-2.3%

1Y

6.7%

Shandong Weigao Group Medical Polymer

HK$20.4b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-7.9%

1Y

-41.0%